GuidelineJCO global oncology2022
Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update.
Guideline in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update.JCO global oncology · 2022Guideline
- Adenosquamous carcinoma of the cervix: a case report from a resource-limited setting.International journal of surgery case reports · 2026Article
- Antiproliferative activity, phytochemistry, network pharmacology, molecular docking and gene expression analysis of Maerua edulis extracts against human cervical cancer cell line.BMC complementary medicine and therapies · 2026Article
- Radiation-Induced Carotid Artery Disease: Pathogenesis, Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Assessing disparities in cancer resources distribution in Mexico.BMC health services research · 2025Article
- [Predictive markers in gynaecological, prostate, and breast cancers].Magyar onkologia · 2024Review
- CXCL8 may serve as a potential biomarker for predicting the prognosis and immune response in cervical cancer.Discover oncology · 2024Article
- ASCO Global Guidelines: Methods and Opportunities.JCO global oncology · 2024Article
- Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.